Washington, D.C. 20549



Form 8-K/A




Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 16, 2020




(Exact name of registrant as specified in its charter)





(State or other jurisdiction

of incorporation



(Commission File Number)



(IRS Employer
Identification No.)


675 Massachusetts Avenue, 14th Floor

Cambridge, Massachusetts

(Address of principal executive offices)



(Zip Code)

Registrant’s telephone number, including area code: (857) 242-1600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class    Trading Symbol(s)    Name of each exchange on which registered






Common Stock, $0.001 par value per
   SPRO    The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously reported on the Current Report on Form 8-K (the “Original Filing”) filed by Spero Therapeutics, Inc. (the “Company”) on April 16, 2020, the Company’s Board of Directors (the “Board”) elected Scott Jackson as a director, effective as of April 16, 2020.

At the time of the Original Filing, the Board had not made a determination regarding any committee assignments for Mr. Jackson. This amended Current Report on Form 8-K is being filed to provide the committee assignment information omitted from the Original Filing. On May 11, 2020, the Board appointed Mr. Jackson to the Audit Committee of the Board, effective as of May 15, 2020.

Other than the preceding disclosure, no other disclosure reported in the Original Filing is amended pursuant to this Report.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: May 11, 2020     By:   /s/ Stephen DiPalma
    Name:   Stephen DiPalma
    Title:   Interim Chief Financial Officer and Treasurer